INTRODUCTION {#sec1-1}
============

Adiverse species of microorganisms is found in human oral cavity both at supragingival and subgingival sites. These oral sites are basically the area where the bacteria accumulate as microbial communities called as dental plaque or dental biofilm.\[[@ref1]\]

A disturbed host balance due to the altered composition of biofilm is a known cause of initiation of dental diseases, i.e., dental caries and periodontal diseases. Both dental caries and periodontal diseases have a different etiology which involves bacteria described as metabolic and geographic opposites. The most common site of dental caries is supragingivally whereas periodontal diseases are seen sub gingivally attacking the tooth supporting structures. Dynamics of microbiota causing these diseases may also affect the treatment of either.\[[@ref2]\]

Dental caries caused by cariogenic plaque which comprises of mainly of low-pH streptococci, predominantly *Streptococcus mutans*, *Streptococcus oralis*, *Streptococcus mitis*, *Rothia, actinomyces*, *Lactobacilli*, and *Bifidobacterium* species whereas periodontal disease which is a cellular inflammatory response of gingiva, and surrounding connective tissue is caused due to the bacterial accumulations seen on the teeth. As it is known that the etiology of periodontitis is very complex (Ledder *et al*., 2007); however, researches have shown the involvement of several key species in the causation of periodontal diseases which include *Porphyromonas gingivalis* (Pg), *Treponema denticola*, *Prevotella intermedia* (Pi), *Aggregatibacter actinomycetemcomitans* (Aa), and *Fusobacterium nucleatum* (Fn).

Developing a better and effective diagnosis and a cost-effective means of curing periodontitis is required. These oral diseases can be prevented by the inhibition of bacterial plaque and biofilm on the tooth surfaces. This may include the mechanical debridement and the use of antimicrobial agents which are a quick and inexpensive means of augmenting mechanical periodontal debridement.\[[@ref3]\]

Studies have shown the inhibitory effect of various antimicrobial agents such as antibiotics, fluorides, povidone-iodine, triclosan, and chlorhexidine on the bacteria grown on oral surfaces. However, these agents might have some side effects which include gastrointestinal irritation, tooth staining, and most importantly, risk of developing antimicrobial resistance; hence, a search of safe, novel and natural bioactive compounds that interfere with biofilm development is required.

Medicinal plants and edible food products having natural, antimicrobial properties, such as phenolic compounds and their subclasses, coumarins, flavonoids, and essential oils, have been studied in relation to pharmaceutical and therapeutical applications in different fields such as medicine and dentistry.\[[@ref1]\]

Medicinal mushrooms, including *Lentinula edodes* or shiitake, have been used in Asia for centuries and is known to have numerous health benefits shiitake mushroom contain many chemical compounds that protect DNA from oxidative damage.\[[@ref4]\]

They are unique in sense because they contain important essential amino acids and essential fatty acids, i.e., linolenic acid. This helps in various functions such as weight loss, boost immune system, destroy cancer cells, improve cardiovascular system health has antimicrobial properties, provide vitamin D, etc. However, still, shiitake has not as yet been assessed for its oral health benefits.

Hence, this study aims to analyze the inhibitory and antibacterial efficacy of shiitake mushroom extracts on periodontal pathogens (minimum inhibitory concentration \[MIC\]) and to determine the time-kill curve for the periodontal pathogens.

MATERIALS AND METHODS {#sec1-2}
=====================

Procurement of material {#sec2-1}
-----------------------

The dried shiitake mushroom weighing about 50 g was obtained from the food store \[[Figure 1](#F1){ref-type="fig"}\]. The obtained dried mushroom was then crushed into a dried powder which was then used for the preparation of the double extract, i.e., alcohol and aqueous extract.

![Shiitake mushroom (crude form)](JISP-23-216-g001){#F1}

Preparation of mushroom extract {#sec2-2}
-------------------------------

The procedure for the preparation of mushroom extract was carried at a Pharmacy College.

Materials required {#sec2-3}
------------------

For the preparation of the double extract of mushroom following materials were used

Dried shiitake mushroom (50 g) (powdered form)ethanol (100 ml) (99% pure)Distilled water (100 ml)Wide-mouth bottleFilter standFilter paperElectronic water bath (maintained at a temperature of 70°--80° centigrade).

A double extract of mushroom, i.e., aqueous and ethanol extract was prepared by a process called maceration. It involves dividing the dried mushroom powder into two equal halves. A 100 ml of 99% pure ethanol and 100 ml of distilled water were taken into two wide-mouth bottles separately. Then, equal divided halves of mushroom powder were added into the individual bottles and were kept for 24 h. Later on, this was filtered using the filter paper. The filtrate in electronic water bath at temperatures of 70-80 degree C, the filtrate dries off and the so obtained residue left behind is final mushroom extract \[[Figure 2](#F2){ref-type="fig"}\].

![Prepared shiitake mushroom extract](JISP-23-216-g002){#F2}

Determination of minimum inhibitory concentration and time-kill curve for the microorganisms {#sec2-4}
--------------------------------------------------------------------------------------------

The obtained mushroom extract was then sent to the Department of Microbiology, for the microbiological procedures, i.e., determination of MIC and time-kill curve for the microorganisms included in the study.

Minimum inhibitory concentration procedural steps {#sec2-5}
-------------------------------------------------

Nine dilutions of the prepared extract were done with brain-heart infusion (BHI) for MICIn the initial tube, 20 μl of drug was added into the 380 μl of BHI brothFor dilutions, 200 μl of BHI broth was added into the next nine tubes separatelyThen, from the initial tube, 200 μl was transferred to the first tube containing 200 μl of BHI broth. This was considered as 10^−1^ dilutionFrom 10^−1^ diluted tube, 200 μl was transferred to the second tube to make 10^−2^ dilutionThe serial dilution was repeated up to 10^-9^ dilution for each drugFrom the maintained stock cultures of required organisms, 5 μl was taken and added into 2 ml of BHI brothIn each serially diluted tube, 200 μl of above culture suspension was addedThe tubes were incubated for 24 h and observed for turbidity \[[Figure 3](#F3){ref-type="fig"}\].

![Minimum inhibitory concentration](JISP-23-216-g003){#F3}

RESULTS {#sec1-3}
=======

The present study on the prepared extract of the shiitake mushroom has tested for the MIC for Pg, Pi, Fn, and Aa, wherein we found that MIC for Pg and Pi was 0.4 μl which was seen in the form of turbidity which concludes that Pg and Pi are highly sensitive for the prepared mushroom extract. At the same time, we found out that Aa showed sensitivity at 0.8 μl showing that it is less sensitive to shiitake mushroom in comparison to Pg and Pi whereas Fn showed the MIC values at 12.5 μl showing its sensitivity at this concentration \[[Table 1](#T1){ref-type="table"}\].

###### 

Minimum inhibitory concentration of shiitake mushroom

  Mushroom extract   100 µl   50   25   12.5   6.25   3.12   1.6   0.8   0.4   0.2
  ------------------ -------- ---- ---- ------ ------ ------ ----- ----- ----- -----
  Pg                 S        S    S    S      S      S      S     S     S     R
  Pi                 S        S    S    S      S      S      S     S     S     R
  Fn                 S        S    S    S      R      R      R     R     R     R
  Aa                 S        S    S    S      S      S      S     S     R     R

Pg -- *Porphyromonas gingivalis*; Pi -- *Prevotella intermedia*; Fn -- *Fusobacterium nucleatum*; Aa -- *Aggregatibacter actinomycetemcomitans*; S -- Sensitive; R -- Resistant; µl -- Microliter

The time-kill curve for the following bacteria was then drawn at their MIC. We found out that Pg at 0.4 μl concentration showed no growth at all whereas Fn at MIC of 12.5 μl showed no growth which indicates Pg is more sensitive than Fn. Pi at its MIC of 0.4 μl showed a gradual decrease in its growth but failed to show no growth after 2-h duration. Aa at its MIC of 0.8 μl had shown a gradual decrease in its growth and after 2-h duration showed absolute no growth \[[Table 2](#T2){ref-type="table"} and [Graph 1](#G1){ref-type="fig"}\].

###### 

Minimum time required to inhibit the growth of the periodontal pathogens in the study (time-kill curve)

  Mushroom extract   0 min   5 min   10 min   30 min   2 h
  ------------------ ------- ------- -------- -------- -----
  Pg                 NG      NG      NG       NG       NG
  Pi                 186     172     154      102      06
  Fn                 NG      NG      NG       NG       NG
  Aa                 138     124     106      56       NG

Pg -- *Porphyromonas gingivalis*; Pi -- *Prevotella intermedia*; Fn -- *Fusobacterium* nucleatum; Aa -- *Aggregatibacter actinomycetemcomitans*; NG -- No growth; Min -- Minutes; h -- Hours

![Time-kill curve: Plotted against X-axis and Y-axis with X-axis showing -- number of microorganisms and Y-axis showing time (in min). Pg -- *Porphyromonas gingivalis*; Pi -- *Prevotella intermedia*; Fn -- *Fusobacterium nucleatum*; Aa -- *Aggregatibacter actinomycetemcomitans*; NG -- No growth; Min -- Minutes; Hrs -- Hours](JISP-23-216-g004){#G1}

DISCUSSION {#sec1-4}
==========

In the present study, the MIC and the time-kill curve of the prepared mushroom extract were studied on four periodontal pathogens, i.e., Pi, Pg, Fn, and *Actinobacillus actinomycetemcomitans*.

The MIC value in the present study ranged from 0.4 μl to 12.5 μl. Pg and Pi showed the least value for MIC, i.e., 0.4 μl whereas Fn and *A. actinomycetemcomitans* were found to be sensitive at 12.5 μl and 0.8 μl. The time-kill curve which demonstrates the bactericidal activity of shiitake mushroom showed absolute no growth of Pg and Fn whereas Pi and *A. actinomycetemcomitans* showed a gradual decrease in the growth.

In the study by Gulhas *et al*. concluded that shiitake essential oil is an effective antibacterial and antibiofilm agent on important oral pathogens. The study elaborated the importance of a major antimicrobial component, i.e., carvacrol an aromatic monoterpenes which showed to disintegrate the outer membrane of Gram-negative bacteria by releasing lipopolysaccharide from their cell wall and increasing membrane permeability.\[[@ref1]\]

In one of the studies by Yano *et al*., showed that some components of mushrooms, including alpha-glucanases, might inhibit the sucrose-induced formation of oral biofilms.\[[@ref5]\]

In another study by Hearst *et al*., it showed the potential antimicrobial effects of shiitake extracts.\[[@ref6]\]

In an *in vitro* study by Ciric *et al*., which compared the effectiveness of shiitake mushroom extract to that of the active component in the leading gingivitis mouthwash, containing chlorhexidine, in an artificial mouth model (constant-depth film fermenter) found out that the shiitake mushroom extract lowered the numbers of some pathogenic taxa without affecting the taxa associated with health, unlike chlorhexidine which has a limited effect on all taxa associated with the health.\[[@ref7]\]

CONCLUSION {#sec1-5}
==========

Within the limits of the study, it can be concluded that shiitake mushroom extract has shown the potential antimicrobial effect on the certain periodontal pathogens. However, in the above-mentioned studies, it was found that some active compound of mushroom-like carvacrol has a significant role as an antimicrobial compound. Hence, further studies to isolate and to identify these active compounds require to be undertaken. Furthermore, the suitable pharmaceutical delivery system is needed to allow concentrated extract to be prepared and deliver optimally rather than the crude ingestion of the raw materials, which could promote further bacterial resistance.
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